Poli Khouloud, Kowarik Markus, Hamprecht Klaus, Iftner Thomas, Ernemann Ulrike, Ziemann Ulf, Poli Sven
Department of Neurology and Stroke, Eberhard-Karls University, Tübingen, Germany.
Hertie Institute for Clinical Brain Research, Eberhard-Karls University, Tübingen, Germany.
Front Neurol. 2023 Mar 10;14:1149612. doi: 10.3389/fneur.2023.1149612. eCollection 2023.
Acute disseminated encephalomyelitis (ADEM) is an autoimmune disorder of the central nervous system (CNS), which is commonly associated to previous viral infection or immunization. Cases of ADEM with a potential relationship to both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have been reported. We recently published a rare case of a 65-year-old patient who suffered from a corticosteroid- and immunoglobulin-refractory multiple autoimmune syndrome including ADEM following Pfizer-BioNTech coronavirus disease (COVID)-19 vaccination, and whose symptoms largely resolved after repeated plasma exchange (PE). Four months later, the patient was diagnosed with SARS-CoV-2 omicron variant infection after experiencing mild upper respiratory tract symptoms. Few days later, the patient developed severe tetraparesis with magnetic resonance imaging (MRI) showing multiple new inflammatory contrast-enhancing lesions in the left middle cerebellar peduncle, cervical spinal cord, and ventral conus medullaris. Repeated cerebrospinal fluid (CSF) analyses indicated blood-brain barrier damage (increased albumin ratio) without signs of SARS-CoV-2 invasion (mild pleocytosis, no intrathecal antibody production). SARS-CoV-2 specific immunoglobulin G (IgG) were detected in serum and to a much lower degree in CSF with close correlation between both concentrations over time, reflecting antibody dynamics of vaccine- and infection-induced immune response, and blood-brain barrier patency. Daily PE therapy was initiated. Given the patient's lack of improvement after seven PE, treatment with rituximab was considered. After a first dose, however, the patient suffered epididymo-orchitis leading to sepsis, and declined rituximab continuation. At 3-months follow-up, clinical symptoms had dramatically improved. The patient regained walking ability without assistance. This case of recurrent ADEM after COVID-19-vaccination and after subsequent COVID-19-infection strongly supports the hypotheses of neuroimmunological complications in these conditions being promoted by a systemic immune response and mediated by molecular mimicry of, both, viral and vaccine SARS-CoV-2 antigens and CNS self-antigens.
急性播散性脑脊髓炎(ADEM)是一种中枢神经系统(CNS)的自身免疫性疾病,通常与先前的病毒感染或免疫接种有关。已有报告称ADEM病例与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染和疫苗接种均存在潜在关联。我们最近发表了一例罕见病例,一名65岁患者在接种辉瑞-生物科技公司的冠状病毒病(COVID)-19疫苗后患上了包括ADEM在内的对皮质类固醇和免疫球蛋白难治的多发性自身免疫综合征,其症状在反复进行血浆置换(PE)后基本缓解。四个月后,该患者在出现轻微上呼吸道症状后被诊断为感染了SARS-CoV-2奥密克戎变异株。几天后,患者出现严重四肢瘫,磁共振成像(MRI)显示在左中脑桥臂、颈脊髓和脊髓圆锥腹侧有多个新的炎症性强化病灶。反复的脑脊液(CSF)分析表明存在血脑屏障损伤(白蛋白比率升高),但没有SARS-CoV-2侵袭的迹象(轻度淋巴细胞增多,无鞘内抗体产生)。在血清中检测到了SARS-CoV-2特异性免疫球蛋白G(IgG),在脑脊液中的含量则低得多,且两者浓度随时间密切相关,反映了疫苗和感染诱导的免疫反应的抗体动态以及血脑屏障的通畅情况。开始每日进行PE治疗。鉴于患者在7次PE治疗后没有改善,考虑使用利妥昔单抗进行治疗。然而,在首次给药后,患者患上了附睾炎-睾丸炎并导致败血症,因此拒绝继续使用利妥昔单抗。在3个月的随访中,临床症状有了显著改善。患者恢复了独立行走能力。这例在COVID-19疫苗接种后及随后的COVID-19感染后复发ADEM的病例有力地支持了以下假设:在这些情况下,神经免疫并发症是由全身免疫反应促成,并由病毒和疫苗SARS-CoV-2抗原与中枢神经系统自身抗原的分子模拟介导。